<code id='E91BF66A34'></code><style id='E91BF66A34'></style>
    • <acronym id='E91BF66A34'></acronym>
      <center id='E91BF66A34'><center id='E91BF66A34'><tfoot id='E91BF66A34'></tfoot></center><abbr id='E91BF66A34'><dir id='E91BF66A34'><tfoot id='E91BF66A34'></tfoot><noframes id='E91BF66A34'>

    • <optgroup id='E91BF66A34'><strike id='E91BF66A34'><sup id='E91BF66A34'></sup></strike><code id='E91BF66A34'></code></optgroup>
        1. <b id='E91BF66A34'><label id='E91BF66A34'><select id='E91BF66A34'><dt id='E91BF66A34'><span id='E91BF66A34'></span></dt></select></label></b><u id='E91BF66A34'></u>
          <i id='E91BF66A34'><strike id='E91BF66A34'><tt id='E91BF66A34'><pre id='E91BF66A34'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:8
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In